CDMO Blog

close

Subscribe to Email Updates

Popular Stories

Viral Aggregation in Downstream Processing of Lentiviral Vectors
IQ, OQ and PQ: Why Are They Important in the Manufacturing of Cell and Gene Therapies?
CDMOs: The Good, the Great and the Exceptional (and How to Tell the Difference)
Five Steps to Ensure Your Cell and Gene Therapy Product Is GMP Compliant
5 Considerations for Scaling-Up PSC-Derived Cell Therapies
12 May 2021

How CCRM's Unique Approach Enables Client Success

Outsourcing to a contract development and manufacturing organization (...

17 Dec 2020

Five Tips to Help Maximize Your Cell and Gene Therapy Budget

Developing cell and gene therapies (CGTs), from discovery to commercia...

11 Dec 2020

4 Tips from the Experts: How to Tighten Your Timeline from Development to Trial

Responsibly moving a cell or gene therapy forward as quickly as possib...

01 Dec 2020

3 Considerations When Developing Your LVV Program

If you are looking to get a lentiviral vector (LVV) program off the gr...

12 Aug 2020

CDMOs: The Good, the Great and the Exceptional (and How to Tell the Difference)

Outsourcing to a contract development and manufacturing organization (...

27 Mar 2020

Essentials of Auditing in the Manufacturing of Cell and Gene Therapies

Our previous posts on quality management systems and steps to ensure y...

Tell us what you thought about this post.